Vertex Pharma (VRTX) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vertex (VRTX) PT Raised to $125 at Credit Suisse; Raise Probability of Triplet to 75%
April 28, 2017 6:26 AM EDTCredit Suisse raised its price target on Vertex (NASDAQ: VRTX) to $125.00 (from $108.00) while maintaining a Outperform rating.
Analyst Alethia Young raised their probability of success to 75% from 50% to the triplet in the HetMin population. They model $2.1B in peak sales in HetMin.
... More